--- title: "Big Scandal! To get Biden into office, Pfizer delayed the launch of the \"COVID-19 vaccine\"?" description: "According to The Wall Street Journal, Trump has claimed for years that Pfizer deliberately delayed the announcement of positive results from clinical trials, which, if released earlier, could have boo" type: "news" locale: "en" url: "https://longbridge.com/en/news/233375513.md" published_at: "2025-03-27T02:18:09.000Z" --- # Big Scandal! To get Biden into office, Pfizer delayed the launch of the "COVID-19 vaccine"? > According to The Wall Street Journal, Trump has claimed for years that Pfizer deliberately delayed the announcement of positive results from clinical trials, which, if released earlier, could have boosted public confidence in his pandemic response policies, thereby benefiting him in the 2020 presidential election On March 26, The Wall Street Journal published a blockbuster report revealing a sensitive allegation regarding the timing of Pfizer's COVID-19 vaccine announcement. According to the report, a senior scientist who previously worked at Pfizer and later joined GSK told colleagues that **Pfizer deliberately delayed announcing the success of its COVID-19 vaccine in 2020 until after the U.S. elections that year.** Although this scientist personally denied such claims, prosecutors are conducting a thorough investigation into the information provided to them by GSK. The report states that the Manhattan U.S. Attorney's Office has interviewed at least two individuals regarding this allegation, including a GSK executive who recorded conversations with the former Pfizer scientist—this former Pfizer scientist is named Phil Dormitzer, who was responsible for Pfizer's viral vaccine research and development before moving to GSK in 2021 and has since left GSK. For years, Trump has claimed that **Pfizer intentionally delayed announcing positive results from clinical trials, which, if released earlier, could have boosted public confidence in his pandemic policies, thereby benefiting him in the 2020 presidential election.** ## Was the vaccine announcement manipulated? Trump is "haunted" by it Trump has long been troubled by the timing of the Pfizer vaccine's release. According to The Wall Street Journal, shortly after he lost the presidential election in November 2020, Pfizer quickly announced its clinical trial results, which angered him. Reportedly, at that time, scientists and executives from Pfizer and other pharmaceutical companies viewed the effort to develop a COVID-19 vaccine as an all-out race following the outbreak, where being the first not only meant prestige but could also lead to significant financial rewards. Pfizer and eight other pharmaceutical companies, including GSK, also jointly signed a pledge agreeing not to seek government approval for their developing COVID-19 vaccines until they were proven safe and effective. On November 8, 2020, Pfizer live-streamed the reaction of executives learning the results from senior scientists, just a day after Biden won the U.S. election on November 7. Two days later, Pfizer announced that preliminary analysis showed its vaccine could safely protect people from the COVID-19 virus. Shortly after midnight on November 10, Trump posted on social media: > "As I have long said, Pfizer and other companies only announced the vaccine after the election because they didn't have the courage to do it before the election." The report indicates that over the past year, Pfizer executives, including CEO Albert Bourla, have sought to build a relationship with Trump, attending fundraising dinners and planning to hold executive-level retreats at Trump's Mar-a-Lago estate after the 2024 election. According to insiders, **Trump personally asked Bourla whether the vaccine announcement was delayed, to which Bourla denied.** ## Investigation is ongoing Reportedly, during the investigation, prosecutors focused on Dormitzer's account to GSK executives regarding events that occurred at Pfizer in 2020 In response to these allegations, Albert Bourla firmly denied in a statement, stating: > "My colleagues at Pfizer and I did everything possible to obtain emergency use authorization from the FDA at the earliest possible moment. Any other interpretation of my comments regarding the vaccine development progress is incorrect." The 61-year-old Bourla is a participant in the development of Pfizer's COVID-19 vaccine, and after working in academia, he has been engaged in vaccine research in the pharmaceutical industry for nearly twenty years. Pfizer stated that they have not yet received inquiries from prosecutors regarding this matter and emphasized that vaccine development is driven by science and conducted under the guidance of the U.S. Food and Drug Administration (FDA). Pfizer's statement said: > "The tireless efforts of scientists, regulators, and thousands of clinical trial volunteers made this vaccine possible. Pfizer is always ready, willing, and able to explain why any allegations of misconduct are completely absurd." Sources familiar with the investigation revealed to The Wall Street Journal that prosecutors plan to interview third parties in the coming days ### Related Stocks - [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Basilea Pharmaceutica 因在亚洲和中国的 Cresemba 销售获得了里程碑式的付款 | 巴西利亚制药公司（Basilea Pharmaceutica AG）宣布，由于其抗真菌药物 Cresemba（伊沙伏康唑）在亚太地区和中国的强劲销售，触发了一笔 500 万美元的里程碑付款，该药物通过其许可合作伙伴辉瑞（Pfizer）销售。 | [Link](https://longbridge.com/en/news/275271671.md) | | Basilea 将因其抗真菌药物从辉瑞获得 500 万美元的里程碑付款 | Basilea 将从辉瑞获得 500 万美元的里程碑付款，用于抗真菌药物 | [Link](https://longbridge.com/en/news/275275339.md) | | 美股盘前热门交易：辉瑞盘前跌 3.56%；Coreweave 盘前涨 3.16% | 辉瑞盘前跌 3.56%；Coreweave 盘前涨 3.16%；Fatpipe 盘前涨 76.63%；Inlif 盘前涨 47.28%；Texxon 盘前涨 34.21%。 | [Link](https://longbridge.com/en/news/274658583.md) | | 期权热点｜周二 PFE 跌 3%，部分看跌期权飙升 116% | 美东时间 02 月 03 日，辉瑞期权总成交 216437 张，看涨期权占比 59%，看跌期权占比 40%。 | [Link](https://longbridge.com/en/news/274753711.md) | | 专家表示，TrumpRx 在推出时，除了减肥药之外，其影响力有限 | TrumpRx，特朗普总统的新处方药网站，主要关注 GLP-1 减肥药的折扣，为消费者提供有限的节省。在启动时，仅有五家制造商列出了药物，大部分折扣来自辉瑞。专家建议，许多用户可能会通过他们的健康保险找到更好的交易，而不是使用 TrumpR | [Link](https://longbridge.com/en/news/275182608.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.